Stallergenes Reports Successful Asthma Trial in China

Stallergenes S.A. announced positive results from a China Phase III clinical trial that tested Staloral® 300 in adult patients with asthma triggered by dust mites. The French company will use the results to support an application for SFDA approval of its drug, a sublingual immunotherapy. It will also conduct a similar trial of another drug, Actair®, in a slightly different population: patients whose rhinitis is triggered by dust mites. More details...